Zobrazeno 1 - 10 of 31 pro vyhledávání: '"Lindsay E. Clegg"'
1
Akademický článek
Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model‐informed drug development case study
Autor: Lindsay E. Clegg, Lulu Chu, Mats Nagard, David W. Boulton, Robert C. Penland
Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 2, Pp 296-307 (2024)
Abstract Potassium (K+) is the main intracellular cation in the body. Elevated K+ levels (hyperkalemia) increase the risk of life‐threatening arrhythmias and sudden cardiac death. However, the details of K+ homeostasis and the effects of orally adm
Externí odkaz: https://doaj.org/article/13e156a6bf924f898f09a9f1f969e99c
Zobrazit plný text záznamu
2
Akademický článek
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
Autor: Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, David W. Boulton, Marcus Thuresson, Hiddo J. L. Heerspink, Stephanie Gustavson, C. David Sjöström, James A. Ruggles, Adrian F. Hernandez, John B. Buse, Robert J. Mentz, Rury R. Holman
Publikováno v: Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-12 (2019)
Abstract Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanisms. However, evidence
Externí odkaz: https://doaj.org/article/3fa36748485b487cb3cfa5fcb2b66bfd
Zobrazit plný text záznamu
3
Akademický článek
Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
Autor: Yasunori Aoki, Bengt Hamrén, Lindsay E. Clegg, Christina Stahre, Deepak L. Bhatt, Itamar Raz, Benjamin M. Scirica, Jan Oscarsson, Björn Carlsson
Publikováno v: PLoS ONE, Vol 16, Iss 11 (2021)
Objective To assess the reproducibility and clinical utility of clustering-based subtyping of patients with type 2 diabetes (T2D) and established cardiovascular (CV) disease. Methods The cardiovascular outcome trial SAVOR-TIMI 53 (n = 16,492) was use
Externí odkaz: https://doaj.org/article/cf7800888d914e0e9ed7cb148b13ad19
Zobrazit plný text záznamu
4
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR‐TIMI 53 cardiovascular outcomes trials
Autor: Adrian F. Hernandez, Yankang Jing, Lindsay E. Clegg, David W. Boulton, Robert C. Penland, Rury R. Holman, Jiten Vora
Publikováno v: Diabetes, Obesity and Metabolism. 23:1101-1110
Aim To provide evidence on the cardiovascular and renal safety of metformin in chronic kidney disease (CKD) stages 3 to 4. Materials and methods This post hoc analysis compared participants with an estimated glomerular filtration rate (eGFR) of 15 to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07783e36457121ec71912c33b78c1efa
https://doi.org/10.1111/dom.14313
Zobrazit plný text záznamu
5
Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk
Autor: Robert C. Penland, Annemarie B van der Aart-van der Beek, Rury R. Holman, David W. Boulton, Hiddo J.L. Heerspink, Lindsay E. Clegg, Robert J. Mentz, C. David Sjöström
Publikováno v: Diabetes, Obesity & Metabolism
Diabetes, Obesity and Metabolism, 22(12), 2493-2498. Wiley
The effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in patients with type 2 diabetes at high cardiovascular risk are modest or neutral. However, GLP-1RAs may confer clinical benefits in those at high risk of progress
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::270e1130a3a50044844c14f3dc0e921b
https://doi.org/10.1111/dom.14175
Zobrazit plný text záznamu
6
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
Autor: Robert C. Penland, Marcus Thuresson, Robert J. Mentz, James Ruggles, C. David Sjöström, Adrian F. Hernandez, Srinivas Bachina, John B. Buse, Lindsay E. Clegg, Stephanie M. Gustavson, David W. Boulton, Hiddo J.L. Heerspink, Rury R. Holman
Publikováno v: Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-12 (2019)
Cardiovascular Diabetology
Cardiovascular Diabetology, 18(1):138. BioMed Central Ltd.
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanisms. However, evidence on clinic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b87451bb2dd9be2096ba11fff4cdb342
http://link.springer.com/article/10.1186/s12933-019-0942-x
Zobrazit plný text záznamu
7
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class
Autor: Robert C. Penland, Robert Fox, Rury R. Holman, Adrian F. Hernandez, David W. Boulton, Weifeng Tang, Hiddo J.L. Heerspink, Robert J. Mentz, Srinivas Bachina, Lindsay E. Clegg, Marcus Thuresson, Peter Fenici
Publikováno v: Diabetes Care, 42(2), 318-326. AMER DIABETES ASSOC
OBJECTIVE The sodium–glucose cotransporter 2 inhibitors (SGLT2i) empagliflozin and canagliflozin reduce the incidence of major adverse cardiovascular events (MACE), all-cause mortality (ACM), and renal events in cardiovascular outcomes trials, with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f51d4b8bc7c13d13c9ed90509ac1e81e
https://research.rug.nl/en/publications/99fbfd17-b93c-4e22-9815-ca5b744405de
Zobrazit plný text záznamu
8
Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)
Autor: Itamar Raz, Jan Oscarsson, Bengt Hamrén, Yasunori Aoki, Deepak L. Bhatt, Björn Carlsson, Christina Stahre, Lindsay E. Clegg, Benjamin M. Scirica
Publikováno v: PLoS ONE, Vol 16, Iss 11 (2021)
PLoS ONE, Vol 16, Iss 11, p e0259372 (2021)
PLoS ONE
Objective To assess the reproducibility and clinical utility of clustering-based subtyping of patients with type 2 diabetes (T2D) and established cardiovascular (CV) disease. Methods The cardiovascular outcome trial SAVOR-TIMI 53 (n = 16,492) was use
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49d932d8e20d824390a35058b036ebd1
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604302/?tool=EBI
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje